Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients

Type 2 diabetes mellitus is the leading cause of chronic kidney disease (CKD) and almost 40% of type 2 diabetes patients develop diabetic kidney disease (DKD), which is characterized by reduced estimated glomerular filtration rate (eGFR) and/or increased albuminuria. Patients with DKD are at high risk of cardiovascular disease and cardiovascular death; therefore, renal protection strategies are very important for type 2 diabetes patients.

Renin–angiotensin–aldosterone system (RAAS) inhibitors are well-known, classic drugs for DKD therapy. Recently, several clinical trials have reported that some newer glucose-lowering drugs, including sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), have beneficial effects on the kidneys in type 2 diabetes patients. Currently, there are five GLP-1RAs (exenatide, liraglutide, dulaglutide, and semaglutide) approved in the USA and Europe. All GLP-1RAs have shown cardiovascular benefits and safety. Most of these trials have secondary exploratory renal end-points data, and the secondary renal outcomes from GLP-1RA cardiovascular outcome trials suggest a renally protective effect of GLP-1RA. Based on the previous trial results, GLP-1RAs have been recommended in DKD patients if they are contraindicated for or do not tolerate SGLT2 inhibitors.

Mann et al. published an article, “Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials” in The Lancet Diabetes & Endocrinology in November 2020. They carried out a post-hoc analysis of type 2 diabetes patients enrolled in Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) 1–7 trials, to investigate the effects of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg versus comparators on kidney function and safety. The main outcomes were eGFR, urine albumin-to-creatinine ratio (UACR) and reported kidney adverse events. Comparators varied between trials: a placebo was used in SUSTAIN 1, 5 and 6; sitagliptin was used in SUSTAIN 2; exenatide extended release in SUSTAIN 3; insulin glargine in SUSTAIN 4; and dulaglutide was used in SUSTAIN 7.

In SUSTAIN 1–5 and 7, in all active treatments, the declines in eGFR were observed from baseline to week 12; estimated treatment differences (ETD) compared with placebo were −2.15 (95% confidence interval [CI] −3.47 to −0.83) mL/min per 1.73 m² with semaglutide 0.5 mg, and −3.00 (95% CI −4.31 to −1.68) with semaglutide 1.0 mg; eGFR plateaued after 12 weeks. Also, a greater reduction in eGFR was observed from baseline to the end of treatment when semaglutide was used rather than a placebo (ETD −1.58, 95% CI −2.92 to −0.25 with semaglutide 0.5 mg, and −2.02, 95% CI −3.35 to −0.68 with semaglutide 1.0 mg). In SUSTAIN 6, there was a greater reduction in eGFR from baseline to week 16 when semaglutide was used rather than a placebo (ETD −1.29, 95% CI 2.07 to −0.51 with semaglutide 0.5 mg, and −1.56, 95% CI −2.33 to −0.78 with semaglutide 1.0 mg). However, from baseline to week 104, there was no significant difference in eGFR reduction between semaglutide and the placebo (ETD 0.07, 95% CI −0.92 to 1.07 with semaglutide 0.5 mg, and 0.97, 95% CI −0.03 to 1.97 with semaglutide 1.0 mg; Table 1). In SUSTAIN 1–5, at the end of treatment, semaglutide had a greater reduction in UACR compared with the placebo (estimated treatment ratios 0.74, 95% CI 0.64–0.85 for semaglutide 0.5 mg, and 0.68, 95% CI 0.59–0.78 for semaglutide 1.0 mg). In SUSTAIN 6, at the end of treatment, there was as greater reduction in UACR with semaglutide compared with the placebo (estimated treatment ratios 0.75, 95% CI 0.66–0.85 for semaglutide 0.5 mg, and 0.66 95% CI 0.58–0.75 for semaglutide 1.0 mg). There was no difference in the incidence of renal adverse events between the treatment groups and the trials.

In SUSTAIN 1–5 and 7, in the semaglutide groups, eGFR initially decreased and then remained until the end of treatment. The initial decrease in eGFR might be due to dehydration. However, there was no difference in reported acute kidney failure, probably due to dehydration, between semaglutide and comparators. In addition to semaglutide, a slow decrease has been reported after an acute decrease in eGFR in other medications, such as RAAS inhibitors and SGLT2 inhibitors. This might reflect hemodynamic changes with a decrease in intraglomerular pressure. The initial decrease in eGFR observed with these drugs might play a role in attenuating the progression of kidney disease in the long term. The effect of SGLT2 inhibitors on eGFR has been shown to be reversible. Reduced UACR by semaglutide was observed overall across all SUSTAIN trials. A greater reduction in UACR was observed in patients with baseline...
Table 1 | Changes and estimated treatment differences in estimated glomerular filtration rate in Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 1–7 used in report form by Mann et al.

|                | SUSTAIN 1-5 and SUSTAIN 7 | SUSTAIN 6 |
|----------------|---------------------------|-----------|
|                | Semaglutide 0.5 mg (n = 1,332) | Placebo (n = 1,644) | Semaglutide 0.5 mg (n = 823) | Placebo (n = 1,640) |
|                | 0 mg (n = 1,734) | Staglirin 100 mg (n = 407) | dulaglutide 0.75 mg, 1.5 mg (n = 598) | 0.75 mg, 1.5 mg (n = 819) |
| ETD, semaglutide vs placebo (95% CI) | –26 (–34 to –18) | –4 (–16 to 8) | –16 (–19 to 3) | –21 (–24 to –18) |
| Change in eGFR (mL/min per 1.73 m²) | –34 | –34 | –34 | –34 |
| ETD, semaglutide vs placebo (95% CI) | –215 (–347 to –83) | –215 (–347 to –83) | –215 (–347 to –83) | –215 (–347 to –83) |
| Change in eGFR (mL/min per 1.73 m²) | –300 (–431 to –169) | –300 (–431 to –169) | –300 (–431 to –169) | –300 (–431 to –169) |
| Placebo (n = 1,644) | SEMAGlutide Unabated Sustainability in Treatment of Type 2 Diabetes 1–7 used in report form by Mann et al.

Cl, confidence interval; eGFR, estimated glomerular filtration rate; ETD, estimated treatment difference; NA, not analysed; SUSTAIN, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes.
activities. This property makes it possible to have a protective effect against glomerular atherosclerosis, which shares the same predictors and mediators as macrovascular disease.

There are several dedicated kidney outcome trials to evaluate the effects of SGLT2 inhibitors on kidney function – Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) and The Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY). In CREDENCE, canagliflozin showed renoprotective properties by reducing the risk of kidney results by 30% compared with a placebo. In DAPA-CKD, dapagliflozin appeared to have renoprotective properties, and the hazard ratio of death from renal causes or end-stage kidney disease was 0.56 versus a placebo. However, to date, no designated GLP-1RA clinical trial has been published to evaluate renal outcomes as the primary end-point. To investigate the effect of GLP-1RA on kidney function, dedicated renal outcome trials and head-to-head comparison studies are required. There is an on-going placebo-controlled trial of injectable semaglutide on renal outcome – Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW; NCT03819153). The American Diabetes Association guidelines recommend the use of GLP-1RA in CKD and type 2 diabetes patients for whom SGLT2 inhibitors are inadequate. Additional long-term trials of GLP-1RA with primary renal end-points are required to support this guideline. Considering the renoprotective effects of both GLP-1RA and SGLT2 inhibitor through sodium–hydrogen exchanger 3, future clinical trials using GLP-1RA and SGLT2 inhibitors together for DKD will give us very interesting results.

DISCLOSURE
The authors declare no conflict of interest.

Min Kyung Kim, Doo-Man Kim*
Division of Endocrinology, Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea

REFERENCES
1. Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther 2020; 11: 835–844.
2. Mann JF, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 2020; 8: 880–893.
3. Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab 2017; 43 (Suppl 1): 2520–2527.
4. Greco E, Russo G, Giandalia A, et al. GLP-1 receptor agonists and kidney protection. Medicina 2019; 55: 233.
5. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85: 579–589.
6. Moellmann J, Klinkhammer BM, Onstein J, et al. Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy. Diabetes 2018; 67: 2410–2419.
7. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 2015; 41: 183–194.

Doi: 10.1111/jdi.13552